ImMucin for Multiple Myeloma
15 March 2010
Please Comment
Vaxil Bio Therapeutics Ltd. in clinical study of active immunotherapy vaccine. ImMucin is intended to stimulate the patient’s own immune system to control cancer by means of reacting to the natural corresponding MUC1 antigen as expressed on the surface of cancer cells.
Phase I/II clinical study is scheduled to commence in 2010 and will be conducted at the Hadassah Medical Center, Jerusalem.
Leave your response!